Regulatory Submissions For Blood Products At Saudi FDA | 13769
ISSN: 2167-7689
Pharmaceutical Regulatory Affairs: Open Access
Open Access
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The Saudi FDA is a government administration that regulates food, drug, as well as medical devices, whether they are
imported or locally manufactured. The drug sector oversees and controls human and veterinary medicines, and cosmetic
products through constructive regulation policies and guidelines. The main purpose is to ensure the safety, quality, efficacy
and availability of all medicines including pharmaceutics and biologics. Thereof, biological products or biologics are medicinal
products derived from a variety of natural sources such as human or animal tissues, or microbiological origins, they were created
with biotechnology and can be manufactured through diversity of biotech based-methods; they are complex in structure and
not fully characterized, and mainly composed of sugar, protein, or nucleic acids or a combination of these substances, they may
also be living entities. Like pharmaceutical products, biologics intended to prevent or treat diseases and medical conditions, and
can be categorized into a wide range of medicinal products including vaccines, blood and blood components, allergenic extracts,
immunosera, somatic cells, gene and cellular therapy, human cells and tissues, and biosimilars. However, biological products
intended to be marketing in Saudi Arabia must obtain a marketing authorization approval. The approval for biological products
can be achieved once the applications meet the requirements. The applications of biological products can be classified based on
the purpose of the application, as follows: new registration, variation, and renewal. These applications shall go through multi steps
process, which starts with the validation and ends with the final decision of approval of rejection. For that, the drug sector has
developed and adopted many guidelines for industry of biological product. My goal is to provide an overview of this process in
Saudi Arabia and share my experience with it.
Biography
Ali Mohammed Alsamil has completed his Master?s of Biomedical laboratory science at the age of 27 years from Quinnipiac University and Bachelor?s
of science in biochemistry from King Saud University. He is specialist in blood bank and transfusion services. Currently, he is an assessor of blood
products, a senior biomedical laboratory specialist, in the product evaluation and standards setting at drug sector, Saudi FDA.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals